NCT03060720

Brief Summary

This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
271

participants targeted

Target at P75+ for all trials

Timeline
21mo left

Started Feb 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress84%
Feb 2017Feb 2028

First Submitted

Initial submission to the registry

February 15, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 23, 2017

Completed
1 day until next milestone

Study Start

First participant enrolled

February 24, 2017

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 7, 2019

Completed
8.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2028

Expected
Last Updated

March 30, 2026

Status Verified

March 1, 2026

Enrollment Period

2.1 years

First QC Date

February 15, 2017

Last Update Submit

March 25, 2026

Conditions

Pancreatic Cancer

Keywords

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

  • We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool

    Up to 5 years

Secondary Outcomes (3)

  • Evaluate Patient Experience With Genetic Testing

    up to 5 years

  • Summarize patient satisfaction with Genetic counseling

    up to 5 years

  • Number of patients who disclose genetic testing results to relatives

    up to 5 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patient seen at Dana Farber Cancer Institute with a diagnosis of pancreatic ductal adenocarcinoma

You may qualify if:

  • Diagnosis of pancreatic ductal adenocarcinoma
  • Signed initial informed consent
  • Participant agrees to genetic counseling

You may not qualify if:

  • Prospective participant unable to sign informed consent based on referring physician recommendation.
  • Patient has neuroendocrine pancreatic tumor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Matthew B Yurgelun, MD

    Dana-Farber Cancer Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Matthew B. Yurgelun, MD

Study Record Dates

First Submitted

February 15, 2017

First Posted

February 23, 2017

Study Start

February 24, 2017

Primary Completion

April 7, 2019

Study Completion (Estimated)

February 1, 2028

Last Updated

March 30, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)